https://www.selleckchem.com/products/ABT-263.html
In the CONVERT study, treatment with amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) met the primary end point of increased culture conversion by month 6 in patients with treatment-refractory Mycobacterium avium complex lung disease (ALIS plus GBT, 29%[65/224] vsGBT alone, 8.9%[10/112]; P .0001). In patients who achieved culture conversion by month 6 in the CONVERT study, was conversion sustained (negative sputum culture results for 12months with treatment) and durable (negative sputum culture r
Like
Comment
Share
